| Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data M Polkowska, P Ekk-Cierniakowski, E Czepielewska, W Wysoczański, ... Journal of cancer research and clinical oncology 143, 2087-2094, 2017 | 18 | 2017 |
| Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients—Real-world data M Polkowska, P Ekk-Cierniakowski, E Czepielewska, ... European journal of clinical pharmacology 75, 329-334, 2019 | 17 | 2019 |
| Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis P Petryszyn, A Staniak, A Wolosianska, P Ekk-Cierniakowski European journal of gastroenterology & hepatology 31 (11), 1306-1312, 2019 | 16 | 2019 |
| Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: Comparative cost-effectiveness study in Poland P Petryszyn, P Ekk-Cierniakowski, G Zurakowski Therapeutic Advances in Gastroenterology 13, 1756284820941179, 2020 | 9 | 2020 |
| C3435T Polymorphism of the ABCB1 Gene in Polish Patients with Inflammatory Bowel Disease: A Case–Control and Meta-Analysis Study P Petryszyn, R Dudkowiak, A Gruca, E Jaźwińska-Tarnawska, ... Genes 12 (9), 1419, 2021 | 8 | 2021 |
| Health-related quality of life in patients with inflammatory bowel disease in Poland (application of the EQ-5D and self-assessment of health state) P Petryszyn, A Zachariasz, P Ekk-Cierniakowski, M Well Value in Health 18 (7), A629, 2015 | 2 | 2015 |
| The valuation of the Short Inflammatory Bowel Disease Questionnaire for use in economic evaluations P Petryszyn, P Piotrowski, P Ekk-Cierniakowski, A Staniak, M Well JOURNAL OF CROHNS & COLITIS 10, S163-S164, 2016 | 1 | 2016 |
| COST-EFFECTIVENESS OF INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN POLAND P Petryszyn, PÅ Ekk-Cierniakowski, Z Grzegorz ISPOR Europe 2019, 2019 | | 2019 |
| Screening For Asymptomatic Atrial Fibrillation: Its Effectiveness And Cost-Effectiveness Of Repeated Ecg In Poland P Petryszyn, P Niewinski, P Piotrowski, A Staniak, M Well, ... Value in Health 20 (9), A501, 2017 | | 2017 |
| P200 Faecal calprotectin as a marker of relapse in inflammatory bowel disease–its place in the management algorithm and cost effectiveness in Poland P Petryszyn, N Wieckowska, A Trznadel, P Ekk-Cierniakowski, A Staniak, ... Journal of Crohn's and Colitis 11 (suppl_1), S178-S178, 2017 | | 2017 |
| Faecal Calprotectin as A Diagnostic Marker of Inflammatory Bowel Disease in Patients with Gastrointestinal Symptoms-is It Cost-Effective Procedure in Primary Care in Poland? P Petryszyn, A Trznadel, A Staniak, M Well, P Ekk-Cierniakowski Value in Health 19 (7), A696, 2016 | | 2016 |
| Valuation of Eq-5d Health States by Pharmacy Students in Poland (Comparison of Different Methods and with General Population) P Petryszyn, P Ekk-Cierniakowski, K Kempa, A Staniak Value in Health 18 (7), A738, 2015 | | 2015 |
